Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network

. 2020 Oct 05 ; 106 (5) : 1496-1499. [epub] 20201005

Jazyk angličtina Země Itálie Médium electronic

Typ dokumentu dopisy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid33054135

Zobrazit více v PubMed

Rajkumar SV, Harousseau JL, Durie B, et al. . Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-4695. PubMed PMC

Munshi NC, Avet-Loiseau H, Rawstron AC, et al. . Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28-35. PubMed PMC

Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood. 2013;122(6):1088-1089. PubMed PMC

van Dongen JJ, Lhermitte L, Bottcher S, et al. . EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908-1975. PubMed PMC

Kalina T, Flores-Montero J, van der Velden VH, et al. . EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010. PubMed PMC

Flores-Montero J, Sanoja-Flores L, Paiva B, et al. . Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094-2103. PubMed PMC

Kumar S, Paiva B, Anderson KC, et al. . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346. PubMed

Scott SD, Fletcher M, Whitehouse H, et al. . Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use? Cytometry B Clin Cytom. 2019;96(3):201-208. PubMed

Kalina T, Brdickova N, Glier H, et al. . Frequent issues and lessons learned from EuroFlow QA. J Immunol Methods. 2019;475:112520. PubMed

Oliva S, Hofste op Bruinink D, RÍhová L, et al. . Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: results from the EMN02/HO95 phase 3 trial. J Clin Oncol. 2017;35(15_suppl):8011.

Cavo M, Gay F, Beksac M, et al. . Autologous haematopoietic stemcell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, openlabel, phase 3 study. Lancet Haematol. 2020;7(6):e456-e468. PubMed

Paiva B, Puig N, Cedena MT, et al. . Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784-792. PubMed

Sanoja-Flores L, Flores-Montero J, Garces JJ, et al. . Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8(12):117. PubMed PMC

Rawstron AC, Orfao A, Beksac M, et al. . Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431-438. PubMed

Arroz M, Came N, Lin P, et al. . Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90(1):31-39. PubMed

Najít záznam

Citační ukazatele

Možnosti archivace